Abstract:Background and purpose: Systematic treatment for breast cancer largely depends on the status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Discordance in ER, PR and HER2 status between primary breast cancer and distant metastases has been observed in a proportion of patients in previous studies. Liver is one of the frequent metastatic sites of breast cancer. Currently, limited data are available on the receptor conversion between primary breast cancer and matched liver metastases. This study aimed to investigate the prevalence, risk factors and prognostic impact of receptor conversion between primary breast cancer and paired liver metastases. Methods: The data of breast cancer patients who had pathologically confirmed liver metastases from January 2013 to May 2020 at Fudan University Shanghai Cancer Center were retrospectively collected. A total of 353 patients with ER, PR and HER2 status available on both primary breast cancer and matched liver metastases were finally included in this study. ER, PR and HER2 status were interpreted according to the most updated American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. The evolution of receptor status and phenotype from primary to metastatic breast cancer was illustrated using Sankey diagrams. Kappa coefficient and McNemar’s test were used to assess the agreement on receptor status between primary breast cancer and liver metastases. The Kaplan-Meier curves were plotted and survival differences across each group were assessed by log-rank test. Multivariate analyses were performed based on the COX proportional hazard regression model. Results: The total discordance rate of ER, PR and HER2 was 19.5%, 39.4% and 4.8%, respectively (Kappa coefficient: 0.569, 0.258 0.876). In de novo stage Ⅳ patients, the discordance rate of ER, PR and HER2 was 15.2%, 28.3% and 2.2%, respectively. Multivariate analysis showed that previous endocrine therapy before liver re-biopsy was an independent risk factor of PR discordance. None of the variables of interest was found to be associated with discordance in ER or HER2 status. Additionally, 37.9% of the HER2-0 tumors converted to HER2-low. A trend of increase in triple-negative and decrease in hormone receptor (HR)+/HER2- cases were observed in liver metastases. Patients with HR+/HER2- primary breast cancer who converted to triple-negative in liver metastases had a significantly shorter overall survival (OS) than those with consistent HR+/HER2- subtype. Patients with the same subtype in liver metastases shared similar OS. Conclusion: This study confirmed discordance in ER, PR and HER2 status between primary breast cancer and liver metastases. The prognosis of breast cancer patients was determined mainly by the subtype in metastases rather than that in primary disease. Our study underlined the necessity of liver re-biopsy in de novo stage Ⅳ patients with liver metastases. Over one-third of HER2-0 patients converted to HER2-low in liver metastases after reassessment, which enabled them to be treated with new antibody-drug conjugate (ADC).

[Discordance of Estrogen Receptor (ER), Progestin Receptor (PR), and HER-2 Receptor Statuses Between Primary and Metastatic Focuses of Breast Cancer].

Discordance of the Expression of ER,PR and Her-2 receptor statuses between primary breast cancer and recurrent focuses

Breast Cancer Primary Tumor ER Expression Pattern Predicts Its Expression Concordance in Matched Synchronous Lymph Node Metastases

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients

Receptor discordance between primary breast cancer and liver metastases

Human Epidermal Growth Factor Receptor 2 Protein Expression Between Primary Breast Cancer and Paired Asynchronous Local-Regional Recurrences.

Evaluation of Primary and Recurrent Breast Cancer after Giving Adjuvant Therapy in Correlation with the Receptor Status

The Discordance Pattern Of Molecular Sub-Types Between Primary And Metastatic Sites In Chinese Breast Cancer Patients

Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study

Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment

HER2 Discordance Between Paired Primary Gastric Cancer and Metastasis: a Meta-Analysis.

The expressing signification of estrogen receptorβ in breast cancer

Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients

Clinico-pathological features of ER+/PR+ and ER+/PR-breast tumors:a comparative study of 5211 cases

The Variation and Clinical Significance of Hormone Receptors and Her-2 Status from Primary to Metastatic Lesions in Breast Cancer Patients

Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases

Abstract P3-13-11: Response to treatment and prognosis of recurrent breast cancer patients with receptor discordance

Profile and Outcome of Receptor Conversion in Breast Cancer Metastases: a Nation-Wide Multicenter Epidemiological Study.

Discordance of human epidermal growth factor receptor 2‐low status between breast primary and distant metastases with clinical–pathological correlation